Literature DB >> 19326408

Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.

Alejandro Espadas de Arias1, Simone Elizabeth Haworth, Luca Saverio Belli, Patrizia Burra, Giovambattista Pinzello, Marcello Vangeli, Ernesto Minola, Maria Guido, Patrizia Boccagni, Tullia Maria De Feo, Rosanna Torelli, Massimo Cardillo, Mario Scalamogna, Francesca Poli.   

Abstract

In 20% to 30% of infected individuals, hepatitis C virus (HCV) can cause cirrhosis and hepatocellular carcinoma, for which liver transplantation is the best treatment available. HCV re-infection is universal, and hepatitis disease recurrence occurs in most cases with a 30% probability of progression to graft cirrhosis at 5 years post-transplant. The immunological response to HCV involves natural killer (NK) cells and killer cell immunoglobulin-like receptors (KIRs), which specifically recognize human leukocyte antigen (HLA) class I antigens present on target cells. The effector functions of NK cells are influenced by inhibitory KIR interaction with self-HLA class I ligands, with HLA-C being the most predominant. This study examines the roles of KIR genotypes and their HLA ligands in both HCV disease recurrence and its progression. A total of 151 patients were included in the cohort, and their clinical details were recorded. Liver biopsies were used to define the absence/presence of recurrent hepatitis, the degree of fibrosis, and the progression to cirrhosis over a 10-year period. Mismatching of KIR-HLA-C ligands between donor-recipient pairs was associated with the recurrence of hepatitis (P = 0.008). The presence of KIR2DL3 in the recipient correlated with progression to liver fibrosis (P = 0.04). The mismatching of HLA-KIR ligands favored the progression of the recurrent hepatitis to fibrosis only in the presence of KIR2DL3 (P = 0.04). These preliminary results indicate that the KIR genotype and KIR-HLA-C ligand compatibility play roles in the recurrence and progression of hepatitis C disease in liver transplant recipients. Copyright 2009 AASLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326408     DOI: 10.1002/lt.21673

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  10 in total

1.  Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C.

Authors:  Varun Saxena; Jennifer C Lai; Jacqueline G O'Leary; Elizabeth C Verna; Robert S Brown; R Todd Stravitz; James F Trotter; Kartik Krishnan; Norah A Terrault
Journal:  Liver Transpl       Date:  2012-05       Impact factor: 5.799

2.  Comparative analysis of NK-cell receptor expression and function across primate species: Perspective on antiviral defenses.

Authors:  Roberto Biassoni; Elisabetta Ugolotti; Andrea De Maria
Journal:  Self Nonself       Date:  2010-03-06

Review 3.  NK cells, innate immunity and hepatitis C infection after liver transplantation.

Authors:  Anoma Nellore; Jay A Fishman
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

4.  Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype.

Authors:  Marcie Tomblyn; Jo-Anne H Young; Michael D Haagenson; John P Klein; Elizabeth A Trachtenberg; Jan Storek; Stephen R Spellman; Sarah Cooley; Jeffrey S Miller; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-01       Impact factor: 5.742

Review 5.  Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.

Authors:  Alberto Grassi; Giorgio Ballardini
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

6.  Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.

Authors:  J R Vidal-Castiñeira; A López-Vázquez; R Díaz-Peña; R Alonso-Arias; J Martínez-Borra; R Pérez; J Fernández-Suárez; S Melón; J Prieto; L Rodrigo; C López-Larrea
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

7.  Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus.

Authors:  Susanne Knapp; Usama Warshow; Doha Hegazy; Louise Brackenbury; I Neil Guha; Andrew Fowell; Ann-Margaret Little; Graeme J Alexander; William M C Rosenberg; Matthew E Cramp; Salim I Khakoo
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

8.  Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.

Authors:  Valli De Re; Laura Caggiari; Mariangela De Zorzi; Ombretta Repetto; Anna Linda Zignego; Francesco Izzo; Maria Lina Tornesello; Franco Maria Buonaguro; Alessandra Mangia; Domenico Sansonno; Vito Racanelli; Salvatore De Vita; Pietro Pioltelli; Emanuela Vaccher; Massimiliano Berretta; Massimiliano Beretta; Cesare Mazzaro; Massimo Libra; Andrea Gini; Antonella Zucchetto; Renato Cannizzaro; Paolo De Paoli
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

9.  The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection.

Authors:  Itay Shalev; Nazia Selzner; Ahmed Helmy; Katharina Foerster; Oyedele A Adeyi; David R Grant; Gary Levy
Journal:  Rambam Maimonides Med J       Date:  2010-07-02

Review 10.  The natural killer cell response to HCV infection.

Authors:  Golo Ahlenstiel
Journal:  Immune Netw       Date:  2013-10-26       Impact factor: 6.303

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.